Medtronic share price today

Medtronic plc's share price was $101.88 at the close on 6 November 2026. It has been stalling near its high for 5 weeks. That is 15.5% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 15 weeks in a row.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Medtronic plc is in stage 3. The phase helps read everything below.

In the last 52 weeks it traded between $74 and $105, and at that close it sat 89% of the way up from that low.

Over the last 10 years the share price moved +15% while the S&P 500 moved +246%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Medtronic plc paid $2.85 per share over the last four reported quarters. The most recent declaration was $0.72 for Jul 2026. At today's price of $101.88 that is a yield of 2.80%, based on dividends already paid, not a forecast.

A dividend is cash paid out for each share. The 12-month total is the four most recent quarters added together.

Medtronic is on one of our US lists: S&P 500 companies.

Medtronic plc earned $1.5 B of net profit in the Jul 2026 quarter, +41.3% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was $4.8 B. Over 4 years profit has grown −1.2% a year on average. That is 15.1% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned $1.0 B.

For the full year, FY26 profit was $4.8 B (+3.0% on the year before).

Why profit moved: revenue changed +13.7% on a year earlier and the margin moved +0.6 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +13.9% and revenue +9.7%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit.

Medtronic plc reported $9.8 B of revenue in the Jul 2026 quarter, +13.7% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 3.5% a year on average. The last full year, FY26, came in at $36.4 B.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to $37.5 B.

FY26 revenue was $36.4 B, +8.4% on the year before.

Recent pace: the last four quarters grew +9.7% on average, against 3.5% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +9.8%, against +7.3% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +12.3%, against +15.4% a year (rolling over).

Medtronic plc's operating margin was 19.3% in the Jul 2026 quarter, 0.6 percentage points higher than the same quarter a year ago. Across 5 years it has been between 17.8% and 21.6%. The latest quarter is within that range.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +0.6 percentage points on the year while gross margin changed −0.1 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 161% of Medtronic plc's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in $7.3 B of operating cash against $4.8 B of profit. After $1.9 B of spending on assets, $5.4 B was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Medtronic plc does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $5.3 B on assets over the last 3 years. Averaged over those years that is 4.9% of FY26 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $5.3 B over the last 3 years.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Medtronic plc's P/E is 25.1×, in the middle of its own history: higher than 36% of past readings. Its usual P/E (the middle reading) is 26.2×, over 4.5 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.